11.09.2022, 747 Zeichen

Valneva: Valenva, an Austrian/French specialty vaccine company, announced that The Lancet Infectious Diseases (“The Lancet ID”), a peer-reviewed medical journal, has published the Company’s pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.Juan Carlos Jaramillo, Chief Medical Officer of Valneva, said, “This Lancet publication is a strong scientific and developmental validation of the work that has been accomplished at Valneva. We are pleased that more detailed results on our inactivated COVID-19 vaccine are now available to the scientific and broader public health communities.”
Valneva: weekly performance: 1.90%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (05/09/2022)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S24/09: Bernadette Händlhuber

Bildnachweis

Aktien auf dem Radar:UBM, Agrana, CA Immo, Austriacard Holdings AG, EuroTeleSites AG, Polytec Group, Frequentis, Rosgix, EVN, Uniqa, Österreichische Post, AT&S, Rosenbauer, Lenzing, Addiko Bank, Frauenthal, SBO, Verbund, BTV AG, Athos Immobilien, Oberbank AG Stamm, Amag, Flughafen Wien, CPI Europe AG, Semperit, Telekom Austria, Münchener Rück, RWE, Allianz, DAIMLER TRUCK HLD..., Fresenius Medical Care.

---